Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317365 | 1.00 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1OPRD1ITGB3ITGB1 | |
| SCHEMBL17509670 | 0.95 | OPRD1 (0.43) | HSP90AA1HSP90AB1OPRD1ITGB3ITGB1 | |
| SCHEMBL5747935 | 0.82 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1ITGB3ITGB1ITGAV | |
| SCHEMBL6310123 | 0.82 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1ITGB3ITGB1ITGAV | |
| SCHEMBL5746786 | 0.80 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1ITGB3ITGB1ITGAV | |
| SCHEMBL5746789 | 0.80 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1ITGB3ITGB1ITGAV | |
| SCHEMBL6312120 | 0.80 | ITGB3 (0.44) | HSP90AA1HSP90AB1ITGB3ITGB1ITGAV | |
| SCHEMBL15215454 | 0.79 | LMNA (0.43) | HSP90AA1HSP90AB1OPRK1 | |
| SCHEMBL6310168 | 0.79 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1ITGB3ITGB1ITGAV | |
| SCHEMBL5078499 | 0.77 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1ITGB3ITGB1ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | HSP90AA1 3787/4885HSP90AB1 3339/4885OPRD1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.